Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
09/02/2026 17:36
Feb 9 (Reuters) - AB Science SA ABS.PA: AB SCIENCE ANNOUNCED THAT THE FOOD AND DRUG ADMINISTRATION (FDA) GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES (MUMS) FOR MASIVET® IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE SA: IN CASE OF MASIVET APPROVAL IN USA, CO EXPECTS EBITDA GENERATED FROM ANIMAL HEALTH TO COVER PART OF ITS FIXED-COST STRUCTURE AB SCIENCE SA: DISCUSSING DISTRIBUTION AGREEMENTS FOR NEW REGIONS NOT YET COVERED Source text: ID:nGNXbGbSd2 Further company coverage: ABS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease